Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690328 | 0.91 | LMNA (0.80) | SIGMAR1LMNAALDH1A1POLBMC4R | |
| SCHEMBL654308 | 0.87 | DRD4 (0.77) | SIGMAR1LMNADRD4 | |
| SCHEMBL1711188 | 0.87 | DRD4 (0.77) | SIGMAR1LMNAALDH1A1DRD4 | |
| SCHEMBL1415730 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| SCHEMBL2489199 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| SCHEMBL1041303 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| SCHEMBL8188324 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| SCHEMBL576868 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| SCHEMBL242970 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| Hydrochloric Acid SCHEMBL9742129 | 0.86 | DRD4 (0.74) | SIGMAR1LMNADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166615-B2 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7160901-B2 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-09 | — | — | US | disclosed |
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | disclosed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | disclosed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | disclosed |
| EP-1341760-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | disclosed |
| WO-2002036564-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | SIGMAR1 1330/4885LMNA 1494/4885ALDH1A1 1242/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | SIGMAR1 1330/4885LMNA 1494/4885ALDH1A1 1242/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | SIGMAR1 1815/4885LMNA 773/4885ALDH1A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.